Vanguard Capital Management
EDSA icon

Vanguard Capital Management’s Edesa Biotech EDSA Stock Holding History

Vanguard Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$665K Sell
81,839
-4,127
-5% -$37.2K ﹤0.01% 3669
2026
Q1 		$450K Buy
+85,966
New +$258K ﹤0.01% 3694

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management's EDSA Position: Q2 2026 in Review

Vanguard Capital Management reduced its Edesa Biotech (EDSA) stake by 4.8% in Q2 2026, selling an estimated $37.2K and leaving 81,839 shares worth $665K. The position accounts for ﹤0.01% of the portfolio, ranked #3669.

Vanguard Capital Management first reported a position in EDSA in Q1 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

  • Vanguard Capital Management held 81,839 shares of Edesa Biotech worth $665K as of Q2 2026.
  • Vanguard Capital Management sold 4,127 Edesa Biotech shares in Q2 2026, an estimated $37.2K.
  • Edesa Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3669 holding.
  • Vanguard Capital Management first reported a position in Edesa Biotech in Q1 2026 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.